MPEP § 2431 — Sample “Sequence Listing” under WIPO ST.25 (Annotated Rules)
§2431 Sample “Sequence Listing” under WIPO ST.25
This page consolidates and annotates all enforceable requirements under MPEP § 2431, including statutory authority, regulatory rules, examiner guidance, and practice notes. It is provided as guidance, with links to the ground truth sources. This is information only, it is not legal advice.
Sample “Sequence Listing” under WIPO ST.25
This section addresses Sample “Sequence Listing” under WIPO ST.25.
Key Rules
Sequence Listing Content
[Editor Note: This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b). See MPEP §§ 2412 – 2419 for guidance on WIPO ST.26 requirements for applications filed on or after July 1, 2022.]
Citations
| Primary topic | Citation |
|---|---|
| Sequence Listing Content | 37 CFR § 1.831(b) |
| Sequence Listing Content | MPEP § 2412 |
Source Text from USPTO’s MPEP
This is an exact copy of the MPEP from the USPTO. It is here for your reference to see the section in context.
Official MPEP § 2431 — Sample “Sequence Listing” under WIPO ST.25
Source: USPTO2431 Sample “Sequence Listing” under WIPO ST.25 [R-07.2022]
[Editor Note: This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b). See MPEP §§ 2412–2419 for guidance on WIPO ST.26 requirements for applications filed on or after July 1, 2022.]
A sample “Sequence Listing” is included below.
